Advancement in Leishmaniasis Diagnosis and Therapeutics

Guest Editors:

Dr. Fernanda Nazaré Morgado

Dr. Renato Porrozzi

Dr. Fatima Conceição-Silva

Prof. Dr. Maria Inês Fernandes Pimentel

Deadline for manuscript submissions:
closed (28 August 2022)

Message from the Guest Editors

Leishmanias are mainly zoonoses, affecting wild and domestic animals. According to their clinical manifestation, they are classified as tegumentary (TL) and visceral (VL) forms. The TL can lead to irreversible and inaesthetic sequelae, whereas VL can be lethal if not promptly diagnosed and treated. Correct diagnosis and adequate treatment constitute two important pillars of the control measures that demand: a) provision of specific and sensitive diagnostic tools widely available in the endemic regions, for the identification of human and animal cases; b) adequate treatment and management of humans and animals, reducing morbidity and mortality and allowing the interruption of the parasite transmission cycle. Advances in treatment have been limited to a few available drugs.

This Special Topic aims to publish original articles, reviews and mini reviews, case reports, and short communications that are related to testing new drugs, new treatment strategies, identification of target molecules with potential use in treatment, serological, molecular and parasitological diagnosis applicable to improve control of human and animal leishmaniasis.

mdpi.com/si/112539

Special Issue